ICMJE DISCLOSURE FORM

Date:	12/5/2021
Your Name:	Takuji Okusaka
Manuscript Title:	Treatment for postoperative recurrence of pancreatic cancer
Manuscript Number (if known):	CCO-21-87 (CCO-2021-PPTPC-01)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial pla	nning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 m	onths
2	2 Grants or		
	from any entity (if	Novartis Pharma K.K.	my institution
		Pfizer Japan Inc.	my institution
	not indicated in item #1	Ono Pharmaceutical Co., Ltd.	my institution
		Kyowa Hakko Kirin Co., Ltd.	my institution
	above).	Dainippon Sumitomo Pharma Co., Ltd.	my institution
		Eisai Co., Ltd.	my institution
		Eli Lilly Japan K.K.	my institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		AstraZeneca K.K.	my institution
		Chugai Pharmaceutical Co., Ltd.	my institution
		Bristol-Myers K.K	my institution
		MSD K.K.	my institution
		Syneos Health	my institution
		Nano Carrier Co., Ltd.	my institution
		Baxter	my institution
		Taiho Pharmaceutical Co., Ltd.	my institution
3	Royalties or licenses	None	
4	Consulting fees	□ None	
		Meiji Seika Pharma	me
		Nippon Shinyaku Co., Ltd.	me
		Nihon Servier	me
		Taiho Pharmaceutical Co., Ltd.	me
		Daiichi Sankyo Co., Ltd.	me
		Dainippon Sumitomo Pharma Co., Ltd.	me
		Bristol-Myers K.K.	me
		AstraZeneca K.K.	me
		Eisai Co., Ltd.	me
5	Payment or honoraria for	□ None	
	lectures, presentations	AstraZeneca K.K.	me
	, speakers	AbbVie Inc.	me
	bureaus,	Eisai Co., Ltd.	me
	manuscript	Ono Pharmaceutical Co., Ltd.	me
	writing or	Yakult Honsha Co., Ltd.	me
	educational	Daiichi Sankyo Co., Ltd.	me
	events	Taiho Pharmaceutical Co., Ltd.	me
		Takeda Pharmaceutical Co., Ltd	me
		Chugai Pharmaceutical Co., Ltd.	me
		Teijin Pharma Ltd.	me
		Eli Lilly Japan K.K.	me
		Nihon Servier Co., Ltd.	me
		Novartis Pharma K.K.	me
6	Payment for expert testimony	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Shire AstraZeneca K.K. Incyte Corporation Eisai Co., Ltd. Ono Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Takara Bio Inc. Takeda Pharmaceutical Co., Ltd Chugai Pharmaceutical Co., Ltd. Eli Lilly Japan K.K. Nihon Servier Co., Ltd. Novartis Pharma K.K. Bayer Yakuhin, Ltd. Pfizer Japan Inc. Bristol-Myers K.K. Mundipharma K.K.	me me
	fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or		
11	stock or stock options	None None	
12	Receipt of equipment, materials, drugs, medical writing,	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	gifts or other services		
13	Other financial or	⊠ None	
	non-financial interests		

Please place an "X" next to the following statement to indicate your agreement:

☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.